Abstract
We demonstrated that the uracil-DNA glycosylase inhibitor, when delivered to human melanoma cells using protein transduction technology, resulted in a dose and time dependent inhibition of uracil-DNA glycosylase (UNG) and this inhibited cell proliferation. These results suggest that a novel class of inhibitors specifically targeting UNG can be developed as potential anti-cancer agents.
Keywords: uracil-dna glycosylase, uracil-dna glycosylase inhibitor, protein transduction, melanoma
Letters in Drug Design & Discovery
Title: Inhibition of Human Melanoma Cell Replication Using Protein Transduction Technology with a Uracil-DNA Glycosylase Inhibitor
Volume: 2 Issue: 2
Author(s): Maria E. Ariza, Irene Pedersen and M. V. Williams
Affiliation:
Keywords: uracil-dna glycosylase, uracil-dna glycosylase inhibitor, protein transduction, melanoma
Abstract: We demonstrated that the uracil-DNA glycosylase inhibitor, when delivered to human melanoma cells using protein transduction technology, resulted in a dose and time dependent inhibition of uracil-DNA glycosylase (UNG) and this inhibited cell proliferation. These results suggest that a novel class of inhibitors specifically targeting UNG can be developed as potential anti-cancer agents.
Export Options
About this article
Cite this article as:
Ariza E. Maria, Pedersen Irene and Williams V. M., Inhibition of Human Melanoma Cell Replication Using Protein Transduction Technology with a Uracil-DNA Glycosylase Inhibitor, Letters in Drug Design & Discovery 2005; 2 (2) . https://dx.doi.org/10.2174/1570180053175179
DOI https://dx.doi.org/10.2174/1570180053175179 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Circulating Tumor Stem Cells as Biomarkers for Cancer Progression
Recent Patents on Biomarkers Immune Checkpoint Inhibitors in Patients with Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Case Report and Literature Review
Current Cancer Drug Targets Molecular Targeting of ERKs/RSK2 Signaling in Cancers
Current Pharmaceutical Design Seeds of Mung Bean (<i>Vigna radiata</i> (L.) R.Wilczek): Taxonomy, Phytochemistry, Medicinal Uses and Pharmacology
Current Bioactive Compounds Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue
Current Medicinal Chemistry Opposing Functions for the Wilms Tumor Protein 1 (WT1) in Tumorigenesis
Current Pediatric Reviews 99mTechnetium- or Cy7-Labeled Fab(Tocilizumab) as Potential Multiple Myeloma Imaging Agents
Anti-Cancer Agents in Medicinal Chemistry Tribbles-Related Protein Family Members as Regulators or Substrates of the Ubiquitin-Proteasome System in Cancer Development
Current Cancer Drug Targets DNA Methylation: A Possible Target for Current and Future Studies on Cancer?
Epigenetic Diagnosis & Therapy (Discontinued) Formulation Considerations of Gadolinium Lipid Nanoemulsion for Intravenous Delivery to Tumors in Neutron-Capture Therapy
Current Drug Delivery Retinoids as Differentiating Agents in Oncology: A Network of Interactions with Intracellular Pathways as the Basis for Rational Therapeutic Combinations
Current Pharmaceutical Design Targeting ADAM17 Sheddase Activity in Cancer
Current Drug Targets Pharmacological Implications of MMP-9 Inhibition by ACE Inhibitors
Current Medicinal Chemistry Natural Product Gossypol and its Derivatives in Precision Cancer Medicine
Current Medicinal Chemistry 5'-Nucleotidases, Nucleosides and their Distribution in the Brain: Pathological and Therapeutic Implications
Current Medicinal Chemistry Cytokine Antibody Arrays in Biomarker Discovery and Validation
Current Proteomics An Integrative Systems Analysis of High-grade Glioma Cell Lines: TLRs, Wnt, BRCA1, Netrins, STXBP1 and MDH1 Provide Putative Molecular Targets for Therapeutic Intervention
Current Pharmacogenomics and Personalized Medicine Metabolic Enzyme System and Transport Pathways in Chronic Kidney Diseases
Current Drug Metabolism Prevention and Treatment of Bone Metastases
Current Pharmaceutical Design Importance and Limitations of Chemotherapy Among the Available Treatments for Gastrointestinal Tumours
Anti-Cancer Agents in Medicinal Chemistry